Meredith McDonald, MD
Internal Medicine · Richmond, VANPI 1003471954
Payments from drug & device makers
Across 90 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bolton Medical Inc$1K
- Novo Nordisk$396
- AbbVie$144
- Amgen$123
- Abbott$111
- Lilly USA, LLC$102
- plus $633 from 18 others
What the payments were for
- Travel & lodging$1,31146%
- Food & beverage$1,49053%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bolton Medical Inc | 2 | $1,311 |
| Novo Nordisk | 23 | $396 |
| AbbVie | 9 | $144 |
| Amgen | 8 | $123 |
| Abbott | 6 | $111 |
| Lilly USA, LLC | 6 | $102 |
| Pfizer | 5 | $96 |
| Exact Sciences | 4 | $74 |
| AstraZeneca | 4 | $53 |
| Dexcom, Inc. | 3 | $50 |
| Edwards Lifesciences | 3 | $49 |
| GSK | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Boston Scientific | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Merck | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,819 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 40 | $53,868 |
| RybelsusSemaglutide | 24 | $45,661 |
| TrulicityDulaglutide | 22 | $32,157 |
| MounjaroTirzepatide | 30 | $31,723 |
| XareltoRivaroxaban | 18 | $29,044 |
| OzempicSemaglutide | 22 | $25,953 |
| EliquisApixaban | 20 | $21,164 |
| FarxigaDapagliflozin Propanediol | 17 | $17,643 |
| JanuviaSitagliptin Phosphate | 14 | $13,260 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,999 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,642 |
| Rosuvastatin Calcium | 312 | $3,776 |
| Allopurinol | 51 | $2,604 |
| Atorvastatin Calcium | 310 | $2,186 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $396 | $71,61346 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $102 | $63,88052 claims |
| Boehringer IngelheimJardiance | $19 | $53,86840 claims |
| PfizerEliquis | $96 | $21,16420 claims |
| AstraZenecaFarxiga | $53 | $17,64317 claims |
| GSKAnoro Ellipta, Breo Ellipta | $43 | $16,64126 claims |
| MerckJanuvia | $19 | $13,26014 claims |
| AbbVieSynthroid | $144 | $1,54938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Richmond
- Leroy VaughanRichmond$20.8M
- Andrew PoklepovicRichmond$4.6M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.